HR and breast cancer: Additionally, the TAKTIC phase Ib/II trial (NCT03959891) evaluated the efficacy of the AKT-1 inhibitor ipatasertib plus fulvestrant or AI in combination or not with palbociclib in advanced HR+/HER2− BC patients, who progressed on previous CDK4/6i treatment.